Cambridge Epigenetix has used research into the role of the epigenome in disease to develop a non-invasive diagnostic kit for widespread cancer screening.
Sphere Fluidics' microdroplet technology is set to automate the discovery of therapeutic monoclonal antibodies, and transform how the biopharmaceutical industry works in this area.
University programmes like Cambridge Enterprise and Accelerate are helping us to spin-out and nurture the ideas of our researchers and students into beneficial and practicable applications.
